Agreed.
I am thinking of a possible K deal as a pre Christmas bonus that could be delivered as early as this fall. You never know how long it takes to close a deal, until you've dealt with lawyers. A LOI can can be generated relatively quickly. However the final papering can take much longer as additional details and questions come to light. But Cameron's suggestion that a deal could be had a year end, suggests to me they may already be quite a ways down the road with someone. Cameron is known to under promise and over deliver (a welcome departure from past MBX Mgt.)
I expect it to take the form of a sale, resulting in a cash infusion with a continuing LT dividend from the buyer...although many variations are possible.
Regarding VTM and other markets, Cameron suggested the possibility of qualifying to sell into the US market down the road. He didn't bite on other potential world markets, although I can't help but think, if there is a need in certain other countries (e.g where vacinations will never reach where they should be and testing is the only reasonable control over spread), they would likely get a quick pass to sell into such countries, having already met more exacting Cdn (or NA) standards. To me this significantly reduces any risk that the market for VTM dries up (due to a waning Covid crisis in NA). Not to mention the liklihood of a variant enduced long lasting endemic. Not to mention an expected big resurgence in flu dignostics when social distancing returns to normal.
Cameron is also a proponent of multipex testing which IMO will happen in the future (if not MBX it WILL with other Co's). Imagine a worker reports a case of the sniffles, or a cough or an elavated temperature. He/she won't get a pass and be allowed to suffer at his/her desk. More than likely he/she will be sent home, and a diagnostic test will be required. And everyone will want to know...is it Covid?, is it the Flu? what strain? What variant? The mind boggles at the possibilities. Diagnostic testing is here to stay, regardless of what happens with Covid. It will no longer satisfy people to hear that they are Covid negtive. If I'm paying for a test, then tell me what it is!
Finally I like the fact that the shelf life has been certified to be 9 months but it could (will?) at some point, be certified to last one year or more. Governments have learned their lesson and will want to secure supply. They won't expect Just-In-Time delivery. If it expires on the shelf of a hospital or gov't organization, it's better that than being caught with none at all.
Still adding here. Will add more if it falls.
I'm comfortable that the next trading level will be reached with (1) a K deal and or (2) year end results, and or (3) guidance on revenues for fiscal 2022 (dare we dream for another doubling in revenues?)
Add to that the fact that it's too early to discuss the following possibilities for 2022, 2023 and beyond:
- acquisitions (use of cash that will eventually start to accumulate)
- sell out to a Major
- Nasdaq
- dividends
but I am confident that one or more of those possibilties will present down the road, and until then, I can & will hold.
MM